| Steven S Brumfield, MD | |
|
143 Peyton Street, Barboursville, WV 25504 | |
| (304) 697-2035 | |
| (304) 523-1485 |
| Full Name | Steven S Brumfield |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 25 Years |
| Location | 143 Peyton Street, Barboursville, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992745624 | NPI | - | NPPES |
| 3810009422 | Medicaid | WV | |
| 1992745624 | Other | WV | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 20944 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary's Medical Center | Huntington, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valley Health Systems, Inc | 9931017969 | 53 |
| Valley Health Systems, Inc | 9931017969 | 53 |
News Archive
U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius sent a letter to WellPoint urging them to immediately end their practice of dropping health insurance coverage for women with breast cancer, after Reuters reported that the company "has specifically targeted women with breast cancer for aggressive investigation with the intent to cancel their policies."
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Is it possible that the blood of those who have recovered from COVID-19 can help cure those who are now sick?
Pioneering 'printed metal' procedure to create bespoke treatment for early knee osteoarthritis set to be trialled in the UK following MHRA approval.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currently under review by the U.S. Food and Drug Administration for the treatment of moderate to severe nasolabial fold wrinkles.
› Verified 6 days ago
| Entity Name | Valley Health Systems, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902962368 PECOS PAC ID: 9931017969 Enrollment ID: O20040325000570 |
News Archive
U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius sent a letter to WellPoint urging them to immediately end their practice of dropping health insurance coverage for women with breast cancer, after Reuters reported that the company "has specifically targeted women with breast cancer for aggressive investigation with the intent to cancel their policies."
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Is it possible that the blood of those who have recovered from COVID-19 can help cure those who are now sick?
Pioneering 'printed metal' procedure to create bespoke treatment for early knee osteoarthritis set to be trialled in the UK following MHRA approval.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currently under review by the U.S. Food and Drug Administration for the treatment of moderate to severe nasolabial fold wrinkles.
› Verified 6 days ago
| Entity Name | St. Mary's Medical Management, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922155217 PECOS PAC ID: 5890897151 Enrollment ID: O20070216000690 |
News Archive
U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius sent a letter to WellPoint urging them to immediately end their practice of dropping health insurance coverage for women with breast cancer, after Reuters reported that the company "has specifically targeted women with breast cancer for aggressive investigation with the intent to cancel their policies."
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Is it possible that the blood of those who have recovered from COVID-19 can help cure those who are now sick?
Pioneering 'printed metal' procedure to create bespoke treatment for early knee osteoarthritis set to be trialled in the UK following MHRA approval.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currently under review by the U.S. Food and Drug Administration for the treatment of moderate to severe nasolabial fold wrinkles.
› Verified 6 days ago
| Entity Name | Valley Health Systems, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720333461 PECOS PAC ID: 9931017969 Enrollment ID: O20130319000031 |
News Archive
U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius sent a letter to WellPoint urging them to immediately end their practice of dropping health insurance coverage for women with breast cancer, after Reuters reported that the company "has specifically targeted women with breast cancer for aggressive investigation with the intent to cancel their policies."
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Is it possible that the blood of those who have recovered from COVID-19 can help cure those who are now sick?
Pioneering 'printed metal' procedure to create bespoke treatment for early knee osteoarthritis set to be trialled in the UK following MHRA approval.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currently under review by the U.S. Food and Drug Administration for the treatment of moderate to severe nasolabial fold wrinkles.
› Verified 6 days ago
| Entity Name | Valley Health Systems, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518680511 PECOS PAC ID: 9931017969 Enrollment ID: O20230303001765 |
News Archive
U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius sent a letter to WellPoint urging them to immediately end their practice of dropping health insurance coverage for women with breast cancer, after Reuters reported that the company "has specifically targeted women with breast cancer for aggressive investigation with the intent to cancel their policies."
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Is it possible that the blood of those who have recovered from COVID-19 can help cure those who are now sick?
Pioneering 'printed metal' procedure to create bespoke treatment for early knee osteoarthritis set to be trialled in the UK following MHRA approval.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currently under review by the U.S. Food and Drug Administration for the treatment of moderate to severe nasolabial fold wrinkles.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven S Brumfield, MD Po Box 4190, Barboursville, WV 25504-4190 Ph: (304) 399-4405 | Steven S Brumfield, MD 143 Peyton Street, Barboursville, WV 25504 Ph: (304) 697-2035 |
News Archive
U.S. Department of Health and Human Services (HHS) Secretary Kathleen Sebelius sent a letter to WellPoint urging them to immediately end their practice of dropping health insurance coverage for women with breast cancer, after Reuters reported that the company "has specifically targeted women with breast cancer for aggressive investigation with the intent to cancel their policies."
The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins. A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs.
Is it possible that the blood of those who have recovered from COVID-19 can help cure those who are now sick?
Pioneering 'printed metal' procedure to create bespoke treatment for early knee osteoarthritis set to be trialled in the UK following MHRA approval.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currently under review by the U.S. Food and Drug Administration for the treatment of moderate to severe nasolabial fold wrinkles.
› Verified 6 days ago
Dr. Rachel E Yung, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 104 Meadow Pointe, Barboursville, WV 25504 Phone: 304-525-5405 Fax: 304-525-3400 | |
Allan Scott Chamberlain, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 143 Peyton Street, Barboursville, WV 25504 Phone: 304-697-2035 Fax: 304-781-2643 | |
Dr. Caleb Richard Huff, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 143 Peyton St, Barboursville, WV 25504 Phone: 304-697-2035 Fax: 304-781-2643 | |
Dr. Brian E Bower, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 104 Meadow Pointe, Barboursville, WV 25504 Phone: 304-525-5405 Fax: 304-525-3400 | |
Dr. Larry Allen Caserta, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 104 Meadow Pointe, Barboursville, WV 25504 Phone: 304-525-5405 Fax: 304-525-3400 |